Cellectar Biosciences, Inc. (CLRB)
CLRBNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.28
+0.0300 (+2.40%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $12.10m
- P/E
- –
- EPS, last 4 quarters
- $-3.84
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.11 to $4.70
- Average volume
- 109.0k
- Previous close
- $1.25
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $10.00, +681.3% from here
Earnings
next estimate $-0.4600Next report
Sep 2025
+26.2%
Dec 2025
+55.5%
Mar 2026
+1.5%
Jun 2026
-3.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.85m | -$5.69m | -$5.79m | -$7.20m |
| Net income | -$4.44m | -$5.29m | -$5.65m | -$6.93m |
News
8 latest- Cellectar Reports 8-Year Complete Response With Iopofosine I 131; Stock Up RTTNews · Oct 27, 2026
- Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström Patients RTTNews · Oct 15, 2026
- Cellectar's Iopofosine I 131 Shows Positive Data In Waldenström Macroglobulinemia RTTNews · Sep 29, 2026
- Cellectar Biosciences (CLRB) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 20, 2026
- Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline RTTNews · Aug 13, 2026
- Cellectra Reports Positive Phase 2 CLOVER Data For Iopofosine I 131 In Waldenstrom Macroglobulinemia RTTNews · Jun 2, 2026
- Cellectar (CLRB) Q1 2026 Earnings TranscriptThe Motley Fool · May 14, 2026
- Weekly Buzz:FDA Clears Tab-cel Path, Arvinas Wins PROTAC Nod, Novartis Cuts Jobs, Roche Buys PathAI RTTNews · May 8, 2026
The company
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cellectar.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.